person

Rosa G.

Country
Italy
Department
Ophthalmology Clinical Operating Unit

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
0
Sites with multiple studies

Has run more than one trial at 0 of 33 partner sites.

Specializations

Ophthalmology – Glaucoma Therapeutics

Focused on preserving visual function in open angle glaucoma. The work emphasizes neuroprotective strategies.

  • Citicoline eye‑drop formulation
  • Visual field preservation outcomes
  • Adjunctive therapy to intra‑ocular pressure control

Research integrates ocular pharmacology with clinical practice guidelines.

Cardiovascular & Heart Failure Inflammation

Investigates anti‑inflammatory approaches in heart failure with preserved ejection fraction. A parallel focus is on heart failure with mildly reduced ejection fraction.

  • Ziltivekimab monthly subcutaneous administration
  • MACE risk reduction
  • Integration with standard heart‑failure care

Efforts aim to lower cardiovascular mortality linked to systemic inflammation.

Cerebrovascular Stroke Prevention

Evaluates antithrombotic agents to prevent recurrent ischemic stroke. The program also addresses high‑risk transient ischemic attack.

  • Milvexian factor XI inhibition
  • Early mortality reduction within seven days
  • Placebo‑controlled efficacy assessment

Therapeutic goals include lowering recurrence and improving acute outcomes.

Hematologic Oncology – B‑Cell Lymphomas

Explores novel immunotherapies for aggressive diffuse large B‑cell lymphoma. Additional interest lies in indolent follicular lymphoma and marginal zone lymphoma.

  • Epcoritamab bispecific antibody
  • Combination with lenalidomide
  • Rituximab‑based regimen enhancement

Research targets improved response rates in relapsed or refractory disease.

Renal Disease & Systemic Inflammation

Targets cardiovascular risk in patients with chronic kidney disease. The approach emphasizes modulation of systemic inflammation.

  • Ziltivekimab anti‑inflammatory therapy
  • Biomarker‑driven outcome measures
  • Combination with standard of care

Objective is to reduce major adverse cardiovascular events in this high‑risk population.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.